The authors concluded that palliative PSMA-targeted RLT therapy for advanced or metastatic salivary gland cancer with 177Lu-PSMA may be effective, is relatively well tolerated and it could significantly relieve tumor-related symptoms when tumor targeting is sufficient. Here, FOLH1 is linked to neoplasm.